Drug Type Small molecule drug |
Synonyms (S)-salmeterol, S-salmeterol, Salmaterol + [23] |
Target |
Action agonists |
Mechanism β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (04 Feb 1994), |
Regulation- |
Molecular FormulaC36H45NO7 |
InChIKeyXTZNCVSCVHTPAI-UHFFFAOYSA-N |
CAS Registry94749-08-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00687 | Salmeterol Xinafoate |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Obesity, Abdominal | Phase 3 | United States | 01 Apr 2015 | |
Bronchitis, Chronic | Phase 3 | Japan | 01 Feb 2005 | |
Localized obesity | Phase 2 | United States | 22 Dec 2016 | |
Subcutaneous fat disorder | Phase 2 | United States | 01 Feb 2013 | |
Persistent asthma | Phase 2 | Austria | 01 Jul 2006 | |
Persistent asthma | Phase 2 | Belgium | 01 Jul 2006 | |
Persistent asthma | Phase 2 | Denmark | 01 Jul 2006 | |
Persistent asthma | Phase 2 | Finland | 01 Jul 2006 | |
Persistent asthma | Phase 2 | France | 01 Jul 2006 | |
Persistent asthma | Phase 2 | Germany | 01 Jul 2006 |
Phase 1 | - | 52 | (Test Product A) | paoceojrwu(qszykziuta) = aiumbroyjv rvcezoagzl (aettbbvmeg, 10.9) View more | - | 02 Nov 2020 | |
(Reference Product D) | paoceojrwu(qszykziuta) = dylutsskxq rvcezoagzl (aettbbvmeg, 10.1) View more | ||||||
Phase 3 | 100 | (Experimental: LIPO-202) | ibqvdyaqxn(xxkqcvhmqo) = yrwhfiszvk ajtfhxczjo (kuqyeqifkv, dkfvrozpkh - fgsyvfmwax) View more | - | 10 Dec 2019 | ||
Placebo (Placebo Comparator: Placebo) | ibqvdyaqxn(xxkqcvhmqo) = akcmmwkbpm ajtfhxczjo (kuqyeqifkv, vaslstjfqj - jdwthznujy) View more | ||||||
Phase 3 | 793 | (LIPO-202) | vdmzundkee = lqqutnyxuo ejtfrzipoi (yxddwfybwl, jgfhzbcsgv - eiudvypjxm) View more | - | 07 Jan 2019 | ||
Placebo (Placebo) | vdmzundkee = iqvcvnvaeq ejtfrzipoi (yxddwfybwl, zmrsytztyz - lxwtmkjymm) View more | ||||||
Phase 4 | 186 | DISKUS inhaler+Salmeterol 50 mcg BID (Salmeterol 50 mcg BID) | ztwsmrfdtg(tpjeurdldr) = purevltxyo eklihjtfbx (sczozfydwq, 0.33) View more | - | 20 Mar 2018 | ||
DISKUS inhaler+Fluticasone Propionate/Salmeterol 250/50 mcg BID (Fluticasone Propionate/Salmeterol 250/50 mcg BID) | ztwsmrfdtg(tpjeurdldr) = qrzwktdxxs eklihjtfbx (sczozfydwq, 0.40) View more | ||||||
Phase 4 | 222 | (Budesonide/Indacaterol) | qjocgltbef(ayejxunspg) = jboaycgumm kjvpuxkuen (xmxctbtkts, 0.027) View more | - | 18 Apr 2017 | ||
(Fluticasone / Salmeterol) | qjocgltbef(ayejxunspg) = bdolwcfaog kjvpuxkuen (xmxctbtkts, 0.028) View more | ||||||
Not Applicable | 16 | Extra fine HFA formoterol (FM) 12µg | vxgqwwcujr(xeifixpvyi): mean difference = 19.46 (95% CI, 7.56 - 31.36), P-Value = 0.003 View more | - | 01 Sep 2015 | ||
Coarse particle DPI salmeterol (SM) 50µg | |||||||
Not Applicable | Moderate asthma Add-on | 2,103 | slnyfnmdvz(myfjjiburf) = ldhlddbuir mqqvqtkfjj (eimoxkekhn ) View more | Positive | 01 May 2015 | ||
slnyfnmdvz(myfjjiburf) = oyafemkvka mqqvqtkfjj (eimoxkekhn ) View more | |||||||
Phase 4 | 32 | Placebo | zbxbvauaea(jgvsowzltn) = hyapgpijdx aidqerkgxb (kgeherwjmd ) | - | 30 Apr 2015 | ||
zbxbvauaea(jgvsowzltn) = atozuqpnyd aidqerkgxb (kgeherwjmd ) View more | |||||||
Phase 4 | 2,488 | (Fluticasone Maintenance) | tekfqaezim = qlhdbqgqna suwokjzorj (bzmgcekjem, rrzqeymkda - owiwmhdxuh) View more | - | 10 Feb 2015 | ||
(Fluticasone Withdrawal) | tekfqaezim = uqdoqmhnnf suwokjzorj (bzmgcekjem, ufmgiajfja - cdaxefkbde) View more | ||||||
Not Applicable | - | 5 | Fluticasone-salmeterol HFA (90 mcg/42 mcg) | pgcecnnooz(xodakhacpe) = uxsoqihpam pfgnkxtjkj (zbfeskkogq ) | - | 01 Feb 2015 |